Thalidomide for the treatment of patients with myelodysplastic syndromes

  title={Thalidomide for the treatment of patients with myelodysplastic syndromes},
  author={Corinna Strupp and Ulrich Germing and Manuel A Aivado and E. Misgeld and Rainer Haas and Norbert Gattermann},
We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q− as sole anomaly and three single aberrations. The median thalidomide dose was 400 mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One… CONTINUE READING